News for Healthcare Capital Corp. (HCCCU)

PR NewswireWILMINGTON, Del., June 16, 2025 WILMINGTON, Del., June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",

NRx Pharmaceuticals (NRXP) forms a strategic investor relations partnership with astr partners, targeting investor engagement. The collaboration occurs

Crescent Biopharma completes merger with GlycoMimetics and secures $200 million in financing. Combined company now trades on Nasdaq under ticker CBIO af

**media[607770]**

PR NewswireIRVINE, Calif., March 12, 2025 IRVINE, Calif., March 12, 2025 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or "the Company"), a

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ( American: MTNB) today announced the appointment of biotech industry ve

**media[559689]**

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement...

GlycoMimetics to acquire Crescent Biopharma in a strategic merger

BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigation…

Since its 2011 founding, KiwiCo, a STEM-based toy and activity brand, has generated more than $1 billion in revenue, Fortune has exclusively learned.

Alfred Lin, who just celebrated his 14th year at Sequoia Capital, talks about the frameworks he uses to identify outlier startup founders.

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company...

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and...

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CHAPEL HILL, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3,...

EVP Capital Announces Agreement for Proposed Qualifying Transaction

Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based...

Earnings call: Evogene reports robust growth and strategic partnerships